Business Context and Reporting Period
This Form 8-K Current Report is filed by AVRA Medical Robotics, Inc. (not SS Innovations International, Inc.) on February 23, 2018. The registrant is an emerging growth company incorporated in Florida. The report details unregistered equity sales and significant changes in corporate governance and executive compensation effective March 1, 2018.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data present relates exclusively to equity issuance and compensation conversions:
- Equity Issuance: 218,000 shares of common stock authorized for issuance.
- Valuation: Shares issued to consultants and the Chief Medical Officer were valued at $1.25 per share. Shares issued to the CEO and CFO were valued at $2.00 per share.
- Stock Awards: A 300,000-share award granted to the new Chief Strategy Officer, vesting over five years.
Material Changes
The filing reports the following material changes regarding equity and personnel:
- Unregistered Sales of Equity (Item 3.02):
- 150,000 shares issued to six consultants/service providers for services through December 31, 2017.
- 35,000 shares issued to Dr. Farhan Taghizadeh (CMO) for services from September 1, 2017, to December 31, 2017.
- 19,500 shares issued to CEO Barry F. Cohen and 13,500 shares to CFO A. Christian Schauer in conversion of accrued unpaid compensation.
- Executive Departures and Appointments (Item 5.02):
- A. Christian Schauer: Resigned as Chief Financial Officer and appointed as a non-employee director.
- Nikhil Shah, D.O.: Resigned from the Board of Directors and appointed as Chief Strategy Officer.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future business performance. The primary risks and contingencies disclosed relate to:
- Compensation Structure: The conversion of accrued unpaid compensation for the CEO and CFO into equity, indicating potential cash flow constraints or strategic capital preservation.
- Leadership Transition: The simultaneous resignation of the CFO and a board member, replaced by a new Chief Strategy Officer with a long-term vesting schedule.
Investor Verification Checklist
- Verify the exact amount of accrued unpaid compensation converted to equity for the CEO and CFO.
- Confirm the vesting schedule and performance conditions for the 300,000 shares granted to the new Chief Strategy Officer.
- Review the company's cash position given the conversion of executive salaries to stock.
- Check for any subsequent filings regarding the appointment of a new Chief Financial Officer.